Trial Profile
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) - A Multicentric Phase II Study in Patients With TKI-resistant EGFR-mutated Lung Cancer Exhibiting Early Metabolic Response to Osimertinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms THEROS
- 30 Sep 2022 Status changed from suspended to completed.
- 13 Sep 2022 Results of osimertinib in patients with EGFR-mutated non-small cell lung cancer, presented at the 47th European Society for Medical Oncology Congress.
- 22 Jan 2022 Status changed from recruiting to suspended.